Skip to content
Business Times – Lifestyle
Author:
Praxis Precision Medicines, Inc.
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
March 30, 2026
←
Previous Page
1
2